There is no downtime after treatment, and you may return to normal daily activities immediately while enjoying a renewed sense of vitality
Dobrek L, Nowakowski M, Mazur M, Herman RM, Thor PJ
Semaglutide is administered once weekly via subcutaneous injection, and the thigh is one of three approved injection sites alongside the abdomen and upper arm
supports insulin sensitivity Nervous System: Protects against neurodegeneration and cognitive decline Skin: Improves autoimmune conditions and accelerates wound healing Future Applications of GLP-1 Medications As clinical trials continue, GLP-1 receptor agonists may soon be approved for: Neurodegenerative diseases: Alzheimers, Parkinsons, MS Autoimmune conditions: Psoriasis, RA, Lupus Cardiometabolic syndromes: NAFLD, PCOS, atherosclerosis Pulmonary conditions: Chronic bronchitis, COPD, even long-COVID inflammation Final Thoughts GLP-1 medications are no longer just diabetes or weight loss drugs